Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Harvard Business School
US Army
Cantor Fitzgerald
AstraZeneca
Dow
Healthtrust
Teva
Argus Health

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,967,208

« Back to Dashboard

Which drugs does patent 6,967,208 protect, and when does it expire?

Patent 6,967,208 protects ELIQUIS and is included in one NDA.

This patent has sixty-six patent family members in thirty-five countries.
Summary for Patent: 6,967,208
Title: Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
Abstract:The present application describes lactam-containing compounds and derivatives thereof of Formula I: ##STR1## or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
Inventor(s): Pinto; Donald J. P. (Churchville, PA), Quan; Mimi L. (Yardley, PA), Orwat; Michael J. (New Hope, PA), Li; Yun-Long (Wilmington, DE), Han; Wei (Yardley, PA), Qiao; Jennifer X. (Princeton, NJ), Lam; Patrick Y. S. (Chadds Ford, PA), Koch; Stephanie L. (Newark, DE)
Assignee: Bristol-Myers Squibb Pharma Company (Princeton, NJ)
Application Number:10/245,122
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,967,208
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,967,208

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y Y REDUCING THE RISK OF STROKE ➤ Sign Up
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y Y PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM ➤ Sign Up
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y Y PROPHYLAXIS OF PULMONARY EMBOLISM ➤ Sign Up
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y Y REDUCE THE RISK OF RECURRENT PULMONARY EMBOLISM ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,967,208

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,691,846 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors ➤ Sign Up
7,005,435 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors ➤ Sign Up
6,989,391 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors ➤ Sign Up
7,531,535 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Moodys
US Army
Farmers Insurance
Baxter
Boehringer Ingelheim
US Department of Justice
McKinsey
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.